Intellia Therapeutics, Inc. (NTLA) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low15.2·High15.2
P/B Ratio
↓
2.24
↓-28% vs avg
5yr avg: 3.12
30Y Low1.3·High8.1
ROE
↓
-53.5%
-19% vs avg
5yr avg: -45.1%
30Y Low-189%·High-23%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NTLA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Intellia Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $974M | $1.2B | $2.7B | $2.7B | $8.4B | $3.0B | $693M | $588M | $692M | $454M |
| Enterprise Value | $1.5B | $912M | $1.2B | $2.6B | $2.3B | $8.3B | $2.9B | $654M | $529M | $351M | $181M |
| P/E Ratio → | -3.64 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 19.91 | 74.61 | 51.53 | 253.61 | 52.52 | 16.08 | 19.32 | 26.50 | 27.54 |
| P/B Ratio | 2.24 | 1.45 | 1.32 | 2.58 | 2.17 | 8.06 | 5.78 | 2.57 | 2.12 | 2.30 | 2.16 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 15.16 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 12.57 |
P/E links to full P/E history page with 30-year chart
NTLA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 20.28 | 71.54 | 43.99 | 252.11 | 50.44 | 15.18 | 17.38 | 13.45 | 10.97 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 6.04 |
NTLA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -1420.5% to -923.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -53.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 82.2% | 75.3% | 85.5% | 79.2% | -159.4% | -151.5% | -192.8% | -159.0% | -93.2% |
| Operating Margin | — | — | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% |
| Net Profit Margin | — | — | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -230.9% | -280.4% | -258.6% | -192.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.5% | -53.5% | -54.0% | -42.1% | -41.7% | -34.2% | -33.7% | -36.3% | -29.5% | -26.5% | -22.8% |
| ROA | -40.6% | -40.6% | -41.7% | -34.1% | -33.7% | -27.2% | -26.6% | -29.2% | -23.6% | -20.0% | -16.6% |
| ROIC | — | — | -43.8% | -43.4% | -37.5% | -28.8% | -32.1% | -35.4% | -76.2% | — | — |
| ROCE | — | — | -47.2% | -40.0% | -35.8% | -30.1% | -30.0% | -35.1% | -27.9% | -22.7% | -18.9% |
NTLA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $155M exceeds total debt of $93M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.24 | 0.11 | 0.11 | 0.07 | 0.07 | 0.07 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | 0.02 | -0.11 | -0.32 | -0.05 | -0.23 | -0.14 | -0.21 | -1.13 | -1.30 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -9.12 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($155M) exceeds total debt ($93M)
NTLA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Intellia Therapeutics, Inc.'s current ratio of 5.08x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.67x to 5.08x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.08 | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 | 9.59 | 8.12 | 8.01 | 11.32 | 9.15 |
| Quick Ratio | 5.08 | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 | 9.59 | 8.12 | 8.01 | 11.32 | 9.15 |
| Cash Ratio | 4.33 | 4.33 | 5.43 | 7.92 | 9.42 | 5.95 | 9.30 | 7.85 | 7.74 | 10.86 | 8.89 |
| Asset Turnover | — | — | 0.05 | 0.03 | 0.03 | 0.03 | 0.09 | 0.13 | 0.09 | 0.07 | 0.06 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 53.71 | 366.82 | 26.39 | 22.43 | 13.41 | 39.12 | 90.51 | 146.34 | 142.95 |
NTLA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Intellia Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 6.6% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $108M | $99M | $89M | $77M | $71M | $56M | $47M | $43M | $36M | $35M |
Peer Comparison
Compare NTLA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NTLAYou | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 CRSP | $5B | -8.5 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $38M | -0.4 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 RCKT | $418M | -1.9 | — | — | — | — | -60.3% | -63.2% | — |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ARCT | $260M | -3.8 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ILMN | $22B | 26.2 | 20.1 | 23.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See NTLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NTLA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NTLA vs EDIT
Side-by-side business, growth, and profitability comparison vs Editas Medicine, Inc..
Start ComparisonNTLA — Frequently Asked Questions
Quick answers to the most common questions about buying NTLA stock.
What is Intellia Therapeutics, Inc.'s P/E ratio?
Intellia Therapeutics, Inc.'s current P/E ratio is -3.6x. This places it at the 50th percentile of its historical range.
What is Intellia Therapeutics, Inc.'s ROE?
Intellia Therapeutics, Inc.'s return on equity (ROE) is -53.5%. The historical average is -49.7%.
Is NTLA stock overvalued?
Based on historical data, Intellia Therapeutics, Inc. is trading at a P/E of -3.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.